W. P. Rowe et al.: Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. In: Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.). Band84, Nr.3, Dezember 1953, S.570–573, doi:10.3181/00379727-84-20714, PMID 13134217 (englisch).
H. Tazawa, S. Kagawa, T. Fujiwara: Advances in adenovirus-mediated p53 cancer gene therapy. In: Expert opinion on biological therapy. Band 13, Nummer 11, November 2013, ISSN1744-7682, S. 1569–1583, doi:10.1517/14712598.2013.845662, PMID 24107178.
H. Tazawa, S. Kagawa, T. Fujiwara: Advances in adenovirus-mediated p53 cancer gene therapy. In: Expert opinion on biological therapy. Band 13, Nummer 11, November 2013, ISSN1744-7682, S. 1569–1583, doi:10.1517/14712598.2013.845662, PMID 24107178.
Feng-Cai Zhu et al.: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. In: Lancet (London, England). Band395, Nr.10240, 13. Juni 2020, S.1845–1854, doi:10.1016/S0140-6736(20)31208-3, PMID 32450106, PMC 7255193 (freier Volltext) – (englisch).
Susan P. Buchbinder et al.: Use of adenovirus type-5 vectored vaccines: a cautionary tale. In: The Lancet. Band396, Nr.10260, 31. Oktober 2020, S.e68–e69, doi:10.1016/S0140-6736(20)32156-5, PMID 33091364 (englisch).
Susan J. Morris et al.: Simian adenoviruses as vaccine vectors. In: Future Virology. Band11, Nr.9, 1. September 2016, S.649–659, doi:10.2217/fvl-2016-0070, PMID 29527232, PMC 5842362 (freier Volltext) – (englisch).
Pedro M. Folegatti et al.: Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. In: The Lancet Infectious Diseases. Band20, Nr.7, 1. Juli 2020, S.816–826, doi:10.1016/S1473-3099(20)30160-2, PMID 32325038 (englisch).
César López-Camacho et al.: A Zika vaccine based on chimpanzee adenovirus ChAdOx1 elicits lineage-transcending sterile immunity and prevents colonisation of brain and ovaries. In: bioRxiv. 14. Januar 2019, S.514877, doi:10.1101/514877 (englisch).
César López-Camacho et al.: Assessment of Immunogenicity and Neutralisation Efficacy of Viral-Vectored Vaccines Against Chikungunya Virus. In: Viruses. Band11, Nr.4, 3. April 2019, doi:10.3390/v11040322, PMID 30987160, PMC 6521086 (freier Volltext) – (englisch).
Ahmed O. Hassan et al.: A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2. In: Cell. Band183, Nr.1, 1. Oktober 2020, S.169–184.e13, doi:10.1016/j.cell.2020.08.026, PMID 32931734, PMC 7437481 (freier Volltext) – (englisch).
J. P. Lynch, M. Fishbein, M. Echavarria: Adenovirus. In: Seminars in respiratory and critical care medicine. Band 32, Nummer 4, August 2011, ISSN1098-9048, S. 494–511, doi:10.1055/s-0031-1283287, PMID 21858752 (Review).
H. N. Na, H. Kim, J. H. Nam: Prophylactic and therapeutic vaccines for obesity. In: Clinical and experimental vaccine research. Band 3, Nummer 1, Januar 2014, ISSN2287-3651, S. 37–41, doi:10.7774/cevr.2014.3.1.37, PMID 24427761, PMC 3890448 (freier Volltext) (Review).
W. P. Rowe et al.: Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. In: Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.). Band84, Nr.3, Dezember 1953, S.570–573, doi:10.3181/00379727-84-20714, PMID 13134217 (englisch).
Eugene V. Koonin, Valerian V. Dolja, Mart Krupovic: Origins and evolution of viruses of eukaryotes: The ultimate modularity. In: Virology, Band 2, Nr. 25, Mai 2015, S. 479–480. Epub 12. März 2015, PMC 5898234 (freier Volltext), PMID 25771806
H. Tazawa, S. Kagawa, T. Fujiwara: Advances in adenovirus-mediated p53 cancer gene therapy. In: Expert opinion on biological therapy. Band 13, Nummer 11, November 2013, ISSN1744-7682, S. 1569–1583, doi:10.1517/14712598.2013.845662, PMID 24107178.
H. Tazawa, S. Kagawa, T. Fujiwara: Advances in adenovirus-mediated p53 cancer gene therapy. In: Expert opinion on biological therapy. Band 13, Nummer 11, November 2013, ISSN1744-7682, S. 1569–1583, doi:10.1517/14712598.2013.845662, PMID 24107178.
Feng-Cai Zhu et al.: Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. In: Lancet (London, England). Band395, Nr.10240, 13. Juni 2020, S.1845–1854, doi:10.1016/S0140-6736(20)31208-3, PMID 32450106, PMC 7255193 (freier Volltext) – (englisch).
Susan P. Buchbinder et al.: Use of adenovirus type-5 vectored vaccines: a cautionary tale. In: The Lancet. Band396, Nr.10260, 31. Oktober 2020, S.e68–e69, doi:10.1016/S0140-6736(20)32156-5, PMID 33091364 (englisch).
Susan J. Morris et al.: Simian adenoviruses as vaccine vectors. In: Future Virology. Band11, Nr.9, 1. September 2016, S.649–659, doi:10.2217/fvl-2016-0070, PMID 29527232, PMC 5842362 (freier Volltext) – (englisch).
Pedro M. Folegatti et al.: Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. In: The Lancet Infectious Diseases. Band20, Nr.7, 1. Juli 2020, S.816–826, doi:10.1016/S1473-3099(20)30160-2, PMID 32325038 (englisch).
César López-Camacho et al.: Assessment of Immunogenicity and Neutralisation Efficacy of Viral-Vectored Vaccines Against Chikungunya Virus. In: Viruses. Band11, Nr.4, 3. April 2019, doi:10.3390/v11040322, PMID 30987160, PMC 6521086 (freier Volltext) – (englisch).
Ahmed O. Hassan et al.: A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2. In: Cell. Band183, Nr.1, 1. Oktober 2020, S.169–184.e13, doi:10.1016/j.cell.2020.08.026, PMID 32931734, PMC 7437481 (freier Volltext) – (englisch).
J. P. Lynch, M. Fishbein, M. Echavarria: Adenovirus. In: Seminars in respiratory and critical care medicine. Band 32, Nummer 4, August 2011, ISSN1098-9048, S. 494–511, doi:10.1055/s-0031-1283287, PMID 21858752 (Review).
H. N. Na, H. Kim, J. H. Nam: Prophylactic and therapeutic vaccines for obesity. In: Clinical and experimental vaccine research. Band 3, Nummer 1, Januar 2014, ISSN2287-3651, S. 37–41, doi:10.7774/cevr.2014.3.1.37, PMID 24427761, PMC 3890448 (freier Volltext) (Review).
H. Tazawa, S. Kagawa, T. Fujiwara: Advances in adenovirus-mediated p53 cancer gene therapy. In: Expert opinion on biological therapy. Band 13, Nummer 11, November 2013, ISSN1744-7682, S. 1569–1583, doi:10.1517/14712598.2013.845662, PMID 24107178.
H. Tazawa, S. Kagawa, T. Fujiwara: Advances in adenovirus-mediated p53 cancer gene therapy. In: Expert opinion on biological therapy. Band 13, Nummer 11, November 2013, ISSN1744-7682, S. 1569–1583, doi:10.1517/14712598.2013.845662, PMID 24107178.
J. P. Lynch, M. Fishbein, M. Echavarria: Adenovirus. In: Seminars in respiratory and critical care medicine. Band 32, Nummer 4, August 2011, ISSN1098-9048, S. 494–511, doi:10.1055/s-0031-1283287, PMID 21858752 (Review).
H. N. Na, H. Kim, J. H. Nam: Prophylactic and therapeutic vaccines for obesity. In: Clinical and experimental vaccine research. Band 3, Nummer 1, Januar 2014, ISSN2287-3651, S. 37–41, doi:10.7774/cevr.2014.3.1.37, PMID 24427761, PMC 3890448 (freier Volltext) (Review).